Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Pancreatic Neoplasms 2Glioblastoma 2Triple Negative Breast Neoplasms 1Gliosarcoma 1Glioma 1Breast Neoplasms 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 18Radiation 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Specimen Handling 4Lomustine 4Bevacizumab 4Aminolevulinic Acid 3veliparib 2trametinib 2lutetium Lu 177 dotatate 2dabrafenib 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2Carboplatin 2Biopsy 2varlilumab 1ulixertinib 1tinostamustine 1selinexor 1ruxolitinib 1ribociclib 1relatlimab 1regorafenib 1peposertib 1pembrolizumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × veliparib × 30 days × Clear all
NCT02152982 2026-06-03

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡